Holen Sie sich die Stockscreener-App
11.05
0.05%
-0.005
Schlusskurs vom Vortag:
$11.06
Offen:
$10.97
24-Stunden-Volumen:
405.99K
Relative Volume:
2.07
Marktkapitalisierung:
$597.61M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-5.83%
1M Leistung:
-25.76%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$10.97
$11.84
1-Wochen-Bereich:
$10.90
$12.24
52-Wochen-Spanne:
$10.82
$16.50
Eikon Therapeutics Inc Stock (EIKN) Company Profile
Firmenname
Eikon Therapeutics Inc
Sektor
Branche
Telefon
-
Adresse
-
Compare EIKN vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EIKN
Eikon Therapeutics Inc
|
11.07 | 597.07M | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
457.62 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.61 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
698.92 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
327.18 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
148.46 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Eikon Therapeutics Inc Stock (EIKN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-02 | Eingeleitet | BofA Securities | Buy |
| 2026-03-02 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2026-03-02 | Eingeleitet | JP Morgan | Overweight |
| 2026-03-02 | Eingeleitet | Mizuho | Outperform |
| 2026-03-02 | Eingeleitet | Morgan Stanley | Overweight |
| 2026-02-26 | Eingeleitet | Wedbush | Underperform |
Alle ansehen
Eikon Therapeutics Inc Aktie (EIKN) Neueste Nachrichten
Eikon Therapeutics, Inc.(NasdaqGS: EIKN) added to S&P TMI Index - marketscreener.com
Eikon Therapeutics (EIKN) Stock Analysis Report | Financials & Insights - Benzinga Japan
Eikon Therapeutics (EIKN) grants 25,873-share stock option award to director - Stock Titan
Eikon Therapeutics (EIKN) grants director Kenneth Frazier 25,873 options - Stock Titan
Large stock option grant to Eikon Therapeutics (EIKN) director and officer - Stock Titan
Eikon Therapeutics (EIKN) COO awarded 87,157-share stock option grant - Stock Titan
Eikon Therapeutics Shares Jump 6% as Brokerages Initiate Coverage By Investing.com - Investing.com Canada
Eikon Therapeutics Shares Jump 6% as Brokerages Initiate Coverage - Investing.com UK
BofA initiates Eikon Therapeutics stock with buy rating on platform potential - Investing.com Australia
BofA Securities Initiates Eikon Therapeutics at Buy With $34 Price Target - marketscreener.com
Cantor Fitzgerald Initiates Eikon Therapeutics at Overweight - marketscreener.com
This NextTrip Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Mizuho Initiates Eikon Therapeutics at Outperform With $26 Price Target - marketscreener.com
BofA initiates Eikon Therapeutics stock with buy rating on platform potential By Investing.com - Investing.com South Africa
Morgan Stanley Initiates Eikon Therapeutics at Overweight With $32 Price Target - marketscreener.com
Mizuho initiates Eikon Therapeutics stock coverage with outperform - Investing.com Nigeria
JPMorgan initiates Eikon Therapeutics stock at Overweight By Investing.com - Investing.com Nigeria
Morgan Stanley initiates Eikon Therapeutics stock coverage at overweight By Investing.com - Investing.com South Africa
Morgan Stanley initiates Eikon Therapeutics stock coverage at overweight - Investing.com India
JPMorgan initiates Eikon Therapeutics stock at Overweight - Investing.com UK
Bank of America Global Research recently announced the official initiation of research coverage on biotechnology company Eikon Therapeutics (stock code: EIKN), and assigned an initial "Buy" rating. - Bitget
Bay Area life sciences firms raise $6.1B as three companies go public - The Business Journals
Eikon Therapeutics, Inc.Common Stock (NQ: EIKN - The Chronicle-Journal
Eikon Therapeutics, Inc.: Dividend historical data and projections - marketscreener.com
Eikon Therapeutics, Inc.: Target Price Consensus and Analysts Recommendations | EIKN | US2825641036 - marketscreener.com
Eikon Therapeutics stock drops after Wedbush downgrade By Investing.com - Investing.com Australia
Eikon Therapeutics stock drops after Wedbush downgrade - Investing.com South Africa
Wedbush initiates Eikon Therapeutics stock with underperform rating - Investing.com South Africa
Wedbush initiates Eikon Therapeutics stock with underperform rating By Investing.com - Investing.com Australia
User - The Chronicle-Journal
EIKN Should I Buy - Intellectia AI
ADIA and Platinum Falcon disclose 2.82M EIKN shares (ADIA affiliate ownership) - Stock Titan
EIKN SEC FilingsEikon Therapeutics 10-K, 10-Q, 8-K Forms - Stock Titan
What is the current Price Target and Forecast for Eikon Therapeutics, Inc. (EIKN) - Zacks Investment Research
Insider Stock Purchases: February 10, 2026 - Quiver Quantitative
Eikon Therapeutics Prices $381 Million Initial Public Offering - Global Legal Chronicle
Wall Street Braces For IPO Boom: Goldman Says 2026 Listings Could Hit $160 Billion As Tech, AI Lead - Benzinga
Merck veteran-led Eikon seeks $908M valuation in US IPO - MSN
Eikon Therapeutics completes IPO and updates governance documents - The Globe and Mail
Eikon, Agomab raise $350M total in IPOs, sink in aftermarket: Public Equity Report - biocentury.com
Eikon Therapeutics, Inc (EIKN) Stock Price Today & Analysis - Gotrade
Finance Watch: Four IPOs In One Week - Citeline News & Insights
Merck veteran Perlmutter-led Eikon Therapeutics valued at $860 million in Nasdaq debut - WTAQ
It was supposed to be the biggest week for IPOs in years. But a 'selective' market didn't cooperate - The Business Journals
Eikon Therapeutics, Late-Stage Clinical Oncology Drug Developer, Files for Nasdaq IPO - TradingView
Eikon Therapeutics valued at $860 million in Nasdaq debut - marketscreener.com
Finanzdaten der Eikon Therapeutics Inc-Aktie (EIKN)
Es liegen keine Finanzdaten für Eikon Therapeutics Inc (EIKN) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
2.14%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):